Polarean Imaging: 1 Month to go, 5 Reasons to Research

Polarean Imaging #POLX 1 Month to go, 5 Reasons to Research

Polarean is are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space. 
 
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.
 
In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.
 
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

Right now you can get 25% off the membership fee.

When registering you will see a link entitled: Have a Coupon?

Click that and enter the discount code: D3P1VQEAL9

Twitter

LinkedIn

NOTHING IN THIS VIDEO IS INVESTMENT ADVICE. INVESTING IN THE STOCK MARKET, ESPECIALLY SMALL COMPANIES CAN BE VERY RISKY. PLEASE DO YOUR OWN RESEARCH OR IF YOU ARE UNSURE PLEASE SEEK PROFESSIONAL ADVICE FROM A REGULATED ADVISOR.

[TabulaRasa]

POLeaXed!...down 60% today!...."Let's get into it...." :)

[neilwye]

Took a bit longer than thought but now looks like FDA approval is complete

[AaqibNaeem]

Agree also dvrg is also another ftse company in the making

[martins]

Massive potential here. But only if management hold firm and resist any early acquisition attempts. Next 12 months is going to be very interesting.